April 20, 2010 04:15 ET
Annual Report 2009 Active Biotech AB (publ)
LUND, SWEDEN--(Marketwire - April 20, 2010) -
Active Biotech's Annual Report 2009 is now available for download at
www.activebiotech.com.
The Annual Report will only be digitally distributed.
Lund, April 20, 2010
Active Biotech AB (publ)
Tomas Leanderson
President & CEO
For further information, please contact:
Göran Forsberg
Vice President Investor Relations & Business Development
Tel +46 (0)46 19 11 54
Active Biotech AB (OMX NORDIC: ACTI), headquartered in Sweden, is a
biotechnology company with R&D focus on autoimmune/inflammatory diseases
and
cancer. Projects in pivotal phase are laquinimod, an orally administered
small
molecule with unique immunomodulatory properties for the treatment of
multiple
sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily
renal
cancer. Further key projects in clinical development comprise the three
orally
administered compounds TASQ for prostate cancer, 57-57 for SLE and
RhuDex™
for RA. Please visit www.activebiotech.com for more information.
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is obligated to publish the information contained in this
press
release in accordance with the Swedish Securities Market Act. This
information
was provided to the media for publication on April 20, 2010, at
10:00
a.m.
[HUG#1405573]